What could strengthen or challenge Cerence, Inc.’s outlook?
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Higher potential upsideImproving expectations
Next-FY EPS estimate change · 30 days
Comparable estimates unavailable
+10% or more+5%0%−5%−10% or less
A matching fiscal period and sufficient coverage are required.
Higher risk of downsideWeakening expectations
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
How this is measured
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
Measure / period
Management expectations
Analyst expectations
FY 2026 · Q4
Free cash flow
$76M–$82M
—
Operating cash flow
$81M–$85M
—
FY 2027 · Q1
Revenue
—
69.79M
EPS
—
0.144
FY 2026 · Annual
Free cash flow
$66M–$76M
—
Operating cash flow
$72M–$78M
—
FY 2027 · Annual
Revenue
—
288.87M
EPS
—
0.784
FY 2028 · Annual
Revenue
—
299.01M
EPS
—
1.023
What the Thesis Depends On
4 published thesis conditions, with dated milestones shown separately.
Key Factor
Why It Matters
Current Status
Break Condition
Latest Evidence
Achieve adjusted EBITDA of $60M to $70M in FY 2026
A primary condition in Cerence, Inc.'s published investment case. The stated target is $60M to $70M.
Intact
Adjusted EBITDA falls below $60M in FY 2026
Direct metric needs a verified mapping
The published measure or accounting basis is not supported by an exact source binding.
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management context
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA grew from $39.8M for nine months ended 2026-Q2 in prior year to $65.4M for nine months ended 2026-Q2 current year. Management raised full-year guidance to $66M-$70M. The trajectory is delivering improved profitability.
Delivery assessment Oct 24, 2026
Generate free cash flow near $71M in FY 2026
Free cash flow is expected near $71 million.
Intact
Free cash flow falls below $66M in FY 2026
Free cash flow: $19.62M
FY2026-Q3; GAAP. Published target: $66M to $76M. Target period is not explicitly aligned with this observation.
Source published Aug 6, 202619,620,000 USD · calculatedSource reportLast status assessment Oct 24, 2026Measurement source
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management context
Stated as a priority in 3 of last 3 quarters. Gross margin improved from 75%-76% guidance in 2025-Q4 to 78%-79% guidance in 2026-Q2. Actual GAAP gross margin was 76.0% in 2026-Q2, showing progress but slightly below the top of guidance. The trajectory is mixed but shows improvement.
Delivery assessment Oct 24, 2026
Achieve revenue of $305M to $320M in FY 2026
A primary condition in Cerence, Inc.'s published investment case. The stated target is $305M to $320M.
Intact
Revenue falls below $305M in FY 2026
Revenue: $69.587M
FY2026-Q3; GAAP. Published target: $305M to $320M. Target period is not explicitly aligned with this observation.
Source published Aug 6, 202669,587,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement source
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management context
Stated as a priority in 3 of last 3 quarters. Revenue grew from $60.6M in 2025-Q4 to $64.2M in 2026-Q1, then $69.6M in 2026-Q2. Management reaffirmed full-year guidance of $310M to $320M. The trajectory shows delivering growth consistent with guidance.
Delivery assessment Oct 24, 2026
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Incoming Evidence
Compare these dated observations with the operating requirements above
Expectations trend
Same fiscal period
FY2028 · fiscal year ending 2028-09-30 · fmp
FY2028 EPS: comparable history unavailable.
FY2028 revenue: comparable history unavailable.
Exact estimates & source dates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
FY2028 estimate observations · fmp
Snapshot
EPS
Revenue
EPS / revenue analysts
2026-10-01
Unavailable
Unavailable
2 / 4
2026-10-02
Unavailable
Unavailable
2 / 4
2026-10-03
Unavailable
Unavailable
2 / 4
2026-10-04
Unavailable
Unavailable
2 / 4
2026-10-05
Unavailable
Unavailable
2 / 4
2026-10-06
Unavailable
Unavailable
2 / 4
2026-10-07
Unavailable
Unavailable
2 / 4
2026-10-08
Unavailable
Unavailable
2 / 4
2026-10-09
Unavailable
Unavailable
2 / 4
2026-10-10
Unavailable
Unavailable
2 / 4
2026-10-11
Unavailable
Unavailable
2 / 4
2026-10-12
Unavailable
Unavailable
2 / 4
2026-10-13
Unavailable
Unavailable
2 / 4
2026-10-14
Unavailable
Unavailable
2 / 4
2026-10-15
Unavailable
Unavailable
2 / 4
2026-10-16
Unavailable
Unavailable
2 / 4
2026-10-17
Unavailable
Unavailable
2 / 4
2026-10-18
Unavailable
Unavailable
2 / 4
2026-10-19
Unavailable
Unavailable
2 / 4
2026-10-20
Unavailable
Unavailable
2 / 4
2026-10-21
Unavailable
Unavailable
2 / 4
2026-10-22
Unavailable
Unavailable
2 / 4
2026-10-23
Unavailable
Unavailable
2 / 4
2026-10-24
Unavailable
Unavailable
2 / 4
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
How this is measured
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Outlook in Brief
The evidence, the remaining questions, and what comes next
What's improving
No recovery evidence is reported in the available driver assessments.
Still unresolved / key risks
Achieve adjusted EBITDA of $60M to $70M in FY 2026Direct metric needs a verified mapping
Generate free cash flow near $71M in FY 2026Free cash flow: $19.62M
Improve gross margin to 79%-80% in FY 2026Gross margin: 76.04%
Achieve revenue of $305M to $320M in FY 2026Revenue: $69.587M
Next proof point
Nov 18, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Risk observations as of Oct 23, 2026 · 277 daily observations. Historical moves are not forecasts.
Read detailed Outlook Company context, assumptions & risks
Cerence, Inc. outlook in detail
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
What kind of bet this is
This is a higher-risk growth and profitability-improvement story, not a proven durable compounder. The long-term thesis is intact, with management progressing toward its revenue and adjusted EBITDA goals, though the latest quarter was missed.
What's priced into Cerence, Inc.
The valuation model describes expectations as aligned, with no concentrated fragility flagged, while CRNC carries a premium versus peers. The expectations gap is negative, so the evidence points to limited room for disappointment rather than an unusually low bar. The available evidence does not explain the market’s specific assumptions.
What the fundamentals likely do
Near term, revenue has risen across the reported quarters, and management reaffirmed its FY 2026 revenue guidance. Adjusted EBITDA has improved, and management raised its full-year guidance, while gross margin is progressing but remains below the top of its stated range. Recent misses make the next report an important execution test, especially for guidance.
What Cerence, Inc. hinges on
The multi-year view depends on CRNC sustaining revenue growth and turning improved adjusted profitability into more consistent results. A guidance cut would be a meaningful negative; continued delivery on management’s goals would support the thesis. Rate cuts and strong results from large technology peers are possible sector tailwinds, but do not resolve company-specific execution risk.
Bottom line
Over the next 1 to 3 years, CRNC’s thesis rests on continued growth and improved profitability, with recent misses and elevated risk making delivery uncertain. The valuation evidence looks aligned rather than fragile, but the premium versus peers raises the importance of execution. Not investment advice.
Source: QuarterlyIQ weekly Outlook · Week ending Oct 24, 2026 · Updated
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
